Dry Eye Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for dry eye disease. 16 active patents protecting 2 drugs from 2+ originators. First major cliff: 2031. Daily refresh.

2
Approved drugs
16
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered

Originators in Dry Eye Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Alcon Labs Inc 10 patents Bausch Health 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating dry eye disease. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
31
3
33
1
35
1
36
1
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tryptyr
ACOLTREMON
 Alcon Labs Inc 10 62 — 2031-09-08
Miebo
PERFLUOROHEXYLOCTANE
 Bausch Health 6 50 — 2033-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10028920 Tryptyr method of use 64 2031-09-08
9433679 Tryptyr method of use 64 2031-09-08
9095609 Tryptyr method of use 64 2031-09-08
11850221 Tryptyr method of use 58 2042-12-16
12336971 Tryptyr method of use 58 2042-12-16
10369117 Miebo method of use 53 2033-09-12
10058615 Miebo method of use 53 2033-09-12
10449164 Miebo method of use 53 2033-09-12
10576154 Miebo method of use 53 2035-10-01
10507132 Miebo method of use 53 2037-06-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11357738 Miebo formulation 33 2036-09-29
10507132 Miebo method of use 53 2037-06-21
10576154 Miebo method of use 53 2035-10-01
10369117 Miebo method of use 53 2033-09-12
10058615 Miebo method of use 53 2033-09-12
10449164 Miebo method of use 53 2033-09-12
11850221 Tryptyr method of use 58 2042-12-16
12336971 Tryptyr method of use 58 2042-12-16
10028920 Tryptyr method of use 64 2031-09-08
9433679 Tryptyr method of use 64 2031-09-08

Related